Health Canada approves LIVMARLI tablets for Alagille syndrome cholestatic pruritus

financialpost.com

Health Canada authorized LIVMARLI tablets for Alagille syndrome cholestatic pruritus. This tablet formulation offers an alternative dosing option for patients aged 12 months and older who can swallow pills, complementing the existing oral solution. LIVMARLI is also approved for progressive familial intrahepatic cholestasis, providing flexible treatment choices for rare liver conditions.


With a significance score of 1.9, this news ranks in the top 29% of today's 24961 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Health Canada approves LIVMARLI tablets for Alagille syndrome cholestatic pruritus | News Minimalist